Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
HPC6
MCID: PRS136
MIFTS: 33

Prostate Cancer, Hereditary, 6 (HPC6)

Categories: Cancer diseases, Genetic diseases, Rare diseases, Reproductive diseases
Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Prostate Cancer, Hereditary, 6

About this section

MalaCards integrated aliases for Prostate Cancer, Hereditary, 6:

Name: Prostate Cancer, Hereditary, 6 56 13 71
Prostate Cancer, Susceptibility to 56
Prostate Cancer 56
Hpc6 56

Classifications:

MalaCards categories:
Global: Cancer diseases Genetic diseases Rare diseases
Anatomical: Reproductive diseases
See all MalaCards categories (disease lists)


External Ids:

OMIM 56 609558
MedGen 41 C1836005
UMLS 71 C1836005
Sources

Summaries for Prostate Cancer, Hereditary, 6

About this section
MalaCards based summary : Prostate Cancer, Hereditary, 6, also known as prostate cancer, susceptibility to, is related to prostate cancer and prostate cancer, hereditary, 1. An important gene associated with Prostate Cancer, Hereditary, 6 is HPC6 (Prostate Cancer, Susceptibility To). The drugs Levofloxacin and Ofloxacin have been mentioned in the context of this disorder. Affiliated tissues include prostate, bone and breast.

More information from OMIM: 609558
Sources

Related Diseases for Prostate Cancer, Hereditary, 6

About this section

Diseases in the Prostate Cancer family:

Prostate Cancer, Hereditary, 1 Prostate Cancer, Hereditary, 8
Prostate Cancer, Hereditary, 3 Prostate Cancer, Hereditary, 4
Prostate Cancer, Hereditary, 5 Prostate Cancer, Hereditary, 6
Prostate Cancer, Hereditary, 7 Prostate Cancer, Hereditary, 9
Prostate Cancer, Hereditary, 10 Prostate Cancer, Hereditary, 12
Prostate Cancer, Hereditary, 13 Prostate Cancer, Hereditary, 11
Prostate Cancer, Hereditary, 14 Prostate Cancer, Hereditary, 15
Prostate Cancer, Hereditary, 2 Prostate Carcinoma in Situ

Diseases related to Prostate Cancer, Hereditary, 6 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1192)
# Related Disease Score Top Affiliating Genes
1 prostate cancer 13.2
2 prostate cancer, hereditary, 1 12.8
3 prostate cancer, hereditary, 2 12.8
4 prostate cancer, hereditary, 13 12.7
5 prostate cancer, hereditary, 12 12.7
6 prostate cancer, hereditary, 11 12.7
7 prostate cancer, hereditary, 4 12.7
8 prostate cancer, hereditary, 8 12.5
9 prostate cancer, hereditary, 3 12.5
10 prostate cancer, hereditary, x-linked 1 12.5
11 prostate cancer/brain cancer susceptibility 12.5
12 prostate cancer, hereditary, 9 12.5
13 prostate cancer, hereditary, 7 12.5
14 prostate cancer, hereditary, 10 12.4
15 prostate cancer, hereditary, 15 12.4
16 prostate cancer, hereditary, 14 12.4
17 prostate cancer, hereditary, x-linked 2 12.4
18 prostate cancer, hereditary, 5 12.4
19 prostate cancer aggressiveness quantitative trait locus on chromosome 19 12.3
20 prostate disease 11.7
21 radiation proctitis 11.6
22 alopecia, androgenetic, 1 11.5
23 hereditary breast ovarian cancer syndrome 11.5
24 breast-ovarian cancer, familial 2 11.5
25 gastric cancer, hereditary diffuse 11.5
26 breast-ovarian cancer, familial 1 11.5
27 prostate sarcoma 11.5
28 pachyonychia congenita 3 11.4
29 diethylstilbestrol syndrome 11.3
30 prostatic hypertrophy 11.3
31 prostatic hyperplasia, benign 11.3
32 prostatic adenoma 11.3
33 impotence 11.1
34 suppression of tumorigenicity 12 11.1
35 colorectal adenoma 11.0
36 adenocarcinoma 11.0
37 chronic interstitial cystitis 11.0
38 neutropenia 10.9
39 severe combined immunodeficiency 10.9
40 prostatitis 10.9
41 bladder cancer 10.9
42 sexual disorder 10.9
43 bone disease 10.8
44 bone resorption disease 10.8
45 proctitis 10.8
46 insulin-like growth factor i 10.8
47 body mass index quantitative trait locus 1 10.7
48 breast cancer 10.7
49 hypogonadism 10.7
50 osteoporosis 10.7

Graphical network of the top 20 diseases related to Prostate Cancer, Hereditary, 6:



Diseases related to Prostate Cancer, Hereditary, 6
Sources

Symptoms & Phenotypes for Prostate Cancer, Hereditary, 6

About this section

Clinical features from OMIM:

609558
Sources

Drugs & Therapeutics for Prostate Cancer, Hereditary, 6

About this section

Drugs for Prostate Cancer, Hereditary, 6 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 820)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
2
Ofloxacin Approved Phase 4 82419-36-1 4583
3
Udenafil Approved, Investigational Phase 4 268203-93-6 6918523
4
Etidronic acid Approved Phase 4 2809-21-4, 7414-83-7 3305
5
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
6
Polyestradiol phosphate Approved Phase 4 28014-46-2
7
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
8
Acetaminophen Approved Phase 4 103-90-2 1983
9
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
10
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
11
Nitric Oxide Approved Phase 4 10102-43-9 145068
12
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
13
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
14
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
15
Desflurane Approved Phase 4 57041-67-5 42113
16
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
17
Ondansetron Approved Phase 4 99614-02-5 4595
18
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
19
Fosfomycin Approved Phase 4 23155-02-4 446987
20
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
21
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
22
Zoledronic Acid Approved Phase 4 118072-93-8 68740
23
Denosumab Approved Phase 4 615258-40-7
24
Pasireotide Approved Phase 4 396091-73-9 9941444
25
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
26
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
27
Remifentanil Approved Phase 4 132875-61-7 60815
28
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
29
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
30
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
31
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
32
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
33
Pamidronate Approved Phase 4 40391-99-9 4674
34
Cabergoline Approved Phase 4 81409-90-7 54746
35
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
36
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
37
Cisplatin Approved Phase 4 15663-27-1 2767 441203 84093
38
Carboplatin Approved Phase 4 41575-94-4 10339178 38904 498142
39
Pancrelipase Approved, Investigational Phase 4 53608-75-6
40
4-Aminopyridine Approved Phase 4 504-24-5 1727
41
Testosterone Approved, Experimental, Investigational Phase 4 58-22-0, 481-30-1 10204 6013
42
Testosterone enanthate Approved Phase 4 315-37-7 9416
43
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
44
Methyltestosterone Approved Phase 4 58-18-4 6010
45
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
46
Beta carotene Approved, Nutraceutical Phase 4 7235-40-7
47
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
48
Tyrosine Approved, Investigational, Nutraceutical Phase 4 60-18-4 6057
49
Genistein Investigational Phase 4 446-72-0 5280961
50 Phytoestrogens Phase 4

Interventional clinical trials:

(show top 50) (show all 4909)
# Name Status NCT ID Phase Drugs
1 Intermittent Vs Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer Unknown status NCT00293670 Phase 4 Goserelin (Zoladex)
2 Phase IV Trial Evaluating the Use of Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer Unknown status NCT01352598 Phase 4
3 Comparison of Health Related Quality of Life and Other Clinical Parameters Between ThinSeedâ„¢ and OncoSeedâ„¢ for Permanent Low Dose Rate Implantation in Localized Prostate Cancer Unknown status NCT01379742 Phase 4
4 Efficiency Study of Aspirin to Prevent the Occurrence of Prostate Cancer Unknown status NCT02757365 Phase 4 aspirin;Levofloxacin
5 METformin And Longevity (METAL): A Window of Opportunity Study Investigating Biological Effects of Metformin in Localised Prostate Cancer Unknown status NCT02511665 Phase 4 Metformin;Placebo
6 A Pilot Phase IV Study to Evaluate Variation in Bone Mineral Density, Lean and Fat Body Mass Index Measured by Dual-energy X-ray Absorptiometry in Patients With Prostate Cancer Without Bone Metastasis Treated With Degarelix Unknown status NCT03202381 Phase 4 Degarelix
7 A Randomized, Double-blind, Placebo-controlled, Investigator Initiated Clinical Trial to Evaluate the Efficacy and Safety of Udenafil Dosed Once a Day in Patients With Erectile Dysfunction After Bilateral Nerve-sparing Radical Prostatectomy Unknown status NCT03142542 Phase 4 ZYDENA TAB.75mg(Udenafil 75mg);Placebo Oral Tablet
8 A Randomised Controlled Trial Comparing Combined Intravenous Propofol and Fentanyl Versus Intravenous Propofol Alone for Sedation in Patients Undergoing Transrectal Ultrasound-guided (TRUS) Prostate Biopsy Unknown status NCT02733705 Phase 4 Fentanyl;propofol
9 Use of Proton MR Spectroscopy and 18F-Fluorocholine PET for Breast Cancer Diagnosis, Prediction of Clinical Outcome and Monitoring of Treatment Response to Neoadjuvant Chemotherapy Unknown status NCT01956409 Phase 4 18F-FCH;Magnevist
10 To Investigate Post-procedure Hemorrhage and Cardiovascular Events in Taiwanese Patients Who Continue or Discontinue Low-Dose Aspirin Before Transrectal Prostate Biopsy: a Prospective Randomized Trial Unknown status NCT02744937 Phase 4 Aspirin
11 MRI With a Lymph Node Specific Contrast Agent: an Alternative for CT-Scanning and Lymph Node Dissection in Patients With Prostate Cancer? Unknown status NCT00185029 Phase 4
12 Effect of Enteral Genistein Supplementation on Inflammatory Cytokines, Morbidity and Mortality in Patients With Sepsis Unknown status NCT02796794 Phase 4
13 Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer Completed NCT00219271 Phase 4 Zoledronic acid
14 A Phase IV Interventional Safety Study of ELIGARD® in Prostate Cancer Patients in Asia (ELIGANT) Completed NCT03035032 Phase 4 Leuprolide
15 Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis Completed NCT00241111 Phase 4 zoledronic acid
16 Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis Completed NCT00237159 Phase 4 Zoledronic acid
17 Non-comparative, Opened Multicenter Study to Assess the Efficacy and Safety of ELIGARD 22.5mg in the Treatment of Subjects With Prostate Cancer Completed NCT01511874 Phase 4 ELIGARD 22.5mg
18 Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases Completed NCT00242554 Phase 4 Zoledronic acid
19 Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases Completed NCT00219219 Phase 4 Zoledronic acid
20 Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer Completed NCT00391690 Phase 4 Zoledronic acid
21 A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates Completed NCT00172016 Phase 4 Zoledronic acid
22 Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy. Completed NCT00237146 Phase 4 Zoledronic acid
23 A Multi-center, Single Arm Study of Enzalutamide in Patients With Progressive Metastatic Castration-Resistant Prostate Cancer Previously Treated With Abiraterone Acetate Completed NCT02116582 Phase 4 Enzalutamide
24 Phase IV Study of Safety and Efficacy of Docetaxel in Combination With Prednisone in Advanced Hormone Refractory Prostate Cancer Treatment Completed NCT00280098 Phase 4 docetaxel
25 A Prospective, Single-arm Multicenter Study to Evaluate Effect of Intravenous Zoledronic Acid on Bone Metabolism Given Over 4 Months in Patients With Prostate Cancer or Breast Cancer and Bone Metastasis Completed NCT00334139 Phase 4 Zoledronic Acid
26 Improving Prostate Biopsy Efficiency: The Finasteride Challenge Test Completed NCT01296672 Phase 4 Finasteride;Placebo
27 An Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Mineral Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis Completed NCT00035997 Phase 4 Zometa
28 A Multicenter, Open-label Study to Determine the Effect of iv. Zoledronic Acid on Pain and Quality of Life in Patients With Bone Metastases With or Without Skeletal Related Events (SRE) Resulting From Breast Cancer and Prostate Cancer Completed NCT00434317 Phase 4 Zoledronic acid
29 A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Dutasteride in Extending the Time to Progression of Low-Risk, Localized Prostate Cancer in Men Who Are Candidates for or Undergoing Expectant Management Completed NCT00363311 Phase 4 Dutasteride;Matching placebo
30 An Open Randomised Trial to Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX Monotherapy Induced Gynaecomastia and/or Breast Pain in Prostate Cancer Patients Completed NCT00590213 Phase 4 Casodex 150mg
31 A Prospective, Multicenter, Open-label Clinical Evaluation of the Effect of IV Zoledronic Acid 4mg on PAIN, QUALITY OF LIFE and TIME IN INFUSION CHAIR in Breast Cancer, Multiple Myeloma, and Prostate Cancer Patients With Cancer-related Bone Lesions Completed NCT00029224 Phase 4 zoledronic acid
32 A Multicenter, Single-arm, Open-label, Postmarketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure Completed NCT01977651 Phase 4 enzalutamide
33 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism in Patients With Prostate Cancer: Orchiectomy vs. Triptorelin Completed NCT02102646 Phase 4 Triptorelin
34 A Randomised Pilot Study to Evaluate the Effect(s) of Casodex 150 mg and Zoladex 3.6 mg on Pathological and Genomic Tumour Markers in Subjects Undergoing Radical Prostatectomy for Localised Prostate Carcinoma Completed NCT00293696 Phase 4 bicalutamide (Casodex), goserelin (Zoladex)
35 Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing Androgen Deprivation Therapy for Prostate Cancer Completed NCT00199485 Phase 4 Angelica Sinensis
36 Randomized, Double-Blind, Placebo-Controlled Trial Assessing The Efficacy And Safety Of Dutasteride At Improving Lower Urinary Tract Symptoms In Men With Clinically Localized Prostate Cancer Being Treated With Single-Dose Goserelin, Trans-Urethral Incision Of Prostate, And Interval Brachytherapy Completed NCT00805701 Phase 4 avodart;Placebo
37 A 12 Month Open Label Study of Serum Testosterone Recovery and PSA After Neo-Adjuvant Treatment With Eligard(TM) 22.5mg Used With Radiation Therapy in Patients With Early Prostate Cancer Completed NCT01136226 Phase 4 Eligard (TM)
38 A Randomized Phase IV Study Comparing Enzalutamide Versus Flutamide in CRPC Patients Who Have Failed Combined Androgen Blockade Therapy With Bicalutamide Plus ADT Completed NCT02918968 Phase 4 Enzalutamide;Flutamide
39 A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer Completed NCT00220194 Phase 4 leuprolide acetate
40 A Multicentric, Multinational (China and Russia), Randomised, Open, Controlled Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients Completed NCT01753297 Phase 4 Triptorelin 11.25 mg
41 Does Androgen Suppression Treatment In Prostate Cancer Reduce Myocardial Blood Flow Reserve? Completed NCT01230905 Phase 4
42 The Effect of Zoledronic Acid Compared to Placebo on Bone Mineral Density in Patients Undergoing Androgen Deprivation Therapy Completed NCT00063609 Phase 4 zoledronic acid
43 Effect of Isoflavones on Cognition, Quality of Life and Hot Flashes in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Completed NCT00245518 Phase 4 Isoflavone;Placebos
44 Multicentre, Single Arm, Open Label, Non Controlled Phase IV Clinical Trial to Evaluate Safety of Cabazitaxel (Jevtana) in Combination With Oral Prednisone (or Prednisolone) for the Treatment of Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen Completed NCT02074137 Phase 4 CABAZITAXEL XRP6258;Prednisone;Prednisolone
45 A Pilot Study on Endothelial Function and Cardiovascular Biomarkers in Prostate Cancer (PCa) Patients, With Pre-existing Cardiovascular Disease, Treated With Degarelix vs. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists Completed NCT02475057 Phase 4 Degarelix (LHRH antagonist);LHRH agonist
46 A Phase 4 Study of Zytiga in Poor-risk mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients Who Was Failed the First-line CAB (Combined Androgen Blockade) Therapy Completed NCT02405858 Phase 4 Abiraterone Acetate;Prednisolone
47 A Randomized, Open-label, Parallel-group Study, to Assess the Pharmocodynamic Effect on Dihydrotestosterone Regulated Gene Expression, Longitudinally and in a Dose Dependent Manner, of 0.5mg and 3.5mg Dutasteride Administered Orally Once Daily, for One Year in Men With Symptomatic Benign Prostatic Hyperplasia and During a Two Month Period Between Baseline and Radical Prostatectomy in Men With Biopsy-proven, Clinically Localized Prostate Cancer Completed NCT00375765 Phase 4 Dutasteride
48 A Phase IV Study of Zoledronic Acid Therapy in Patients With Bone Metastases From Breast Cancer or Hormone Resistant Prostate Cancer, or Bone Involvement From Multiple Myeloma, Assessing Long-term Efficacy and Safety Completed NCT00434447 Phase 4 Zoledronic acid
49 A Pilot Study to Assess the Technical Feasibility of Robotic Assisted Laparoscopic Interpositioning of the AVANCETM Nerve Graft for Reconstruction of the Neurovascular Bundle, With a Twenty-four Month Follow-up Term to Assess Efficacy Completed NCT00953277 Phase 4
50 A Randomized Double-Blind Parallel Group Study Comparing Casodex (or Generic Equivalent) 50mg Plus Placebo to Casodex (or Generic Equivalent) 50mg Plus Dutasteride 3.5mg Administered for 18 Months to Men With Prostate Cancer Who Have Failed First-Line Androgen Deprivation Therapy (Assessed by Rising PSA) Followed by a Two-Year Extension Phase Completed NCT00470834 Phase 4 dutasteride;placebo;bicalutamide

Search NIH Clinical Center for Prostate Cancer, Hereditary, 6

Sources

Genetic Tests for Prostate Cancer, Hereditary, 6

About this section
Sources

Anatomical Context for Prostate Cancer, Hereditary, 6

About this section

MalaCards organs/tissues related to Prostate Cancer, Hereditary, 6:

40
Prostate, Bone, Breast, Testes, Lung, Lymph Node, T Cells
Sources

Publications for Prostate Cancer, Hereditary, 6

About this section

Articles related to Prostate Cancer, Hereditary, 6:

# Title Authors PMID Year
1
Family-based association analysis of 42 hereditary prostate cancer families identifies the Apolipoprotein L3 region on chromosome 22q12 as a risk locus. 56
20631155 2010
2
Fine mapping of familial prostate cancer families narrows the interval for a susceptibility locus on chromosome 22q12.3 to 1.36 Mb. 56
18066601 2008
3
Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics. 56
17478474 2007
4
Localization of a prostate cancer predisposition gene to an 880-kb region on chromosome 22q12.3 in Utah high-risk pedigrees. 56
17047086 2006
5
A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. 56
15988677 2005
6
Vitamin D(3) cryosensitization increases prostate cancer susceptibility to cryoablation via mitochondrial-mediated apoptosis and necrosis. 61
21883825 2012
7
Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer. 61
17700570 2007
8
Genetic linkage analysis of prostate cancer families to Xq27-28. 61
11096277 2001
9
Intention to be tested for prostate cancer risk among African-American men. 61
11142417 2000
Sources

Variations for Prostate Cancer, Hereditary, 6

About this section
Sources

Expression for Prostate Cancer, Hereditary, 6

About this section
Search GEO for disease gene expression data for Prostate Cancer, Hereditary, 6.
Sources

Pathways for Prostate Cancer, Hereditary, 6

About this section
Sources

GO Terms for Prostate Cancer, Hereditary, 6

About this section
Sources

Sources for Prostate Cancer, Hereditary, 6

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....